Author Archives: BPI Staff

Evotec lays down $90m to buy Just for kickstarting biologics biz

German services firm Evotec has jumped into the biologics development space through the acquisition of Just.Bio, a platform company working to reduce the cost of goods for proteins. Hamburg, Germany-based Evotec uses its expertise and technologies to help pharma firms discover and develop new small molecule therapies and names Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, and UCB among its partners. Through the addition of Just.Bio for $90 million (€81 million) cash, Evotec has increased its…

CDMO round-up: News from Patheon, Samsung and Sekisui

Patheon will produce an antibody for Cantargia; GI Innovation has signed a second development services deal with Samsung BioLogics; Sekisui Diagnostics is growing its contract microbial manufacturing business. Welcome to Bioprocess Insider’s CDMO round-up. First up in our contract development and manufacturing organization (CDMO) round-up is news from Thermo Fisher’s Patheon, which has been selected to produce CAN04 (nidanilimab) for Cantargia AB. Cantargia already has a contract in place with Celonic (formerly Glycotope Biotechnology) for clinical supply of the monoclonal…

Vibalogics $1.35m expansion feeds ‘booming’ viral vector demand

CDMO Vibalogics has increased its single-use bioreactor and purification capacity at its site in northern Germany on the back of growing demand for oncolytic virus and viral vector production. The German contract development and manufacturing organization (CDMO) has added a new manufacturing line consisting of a 50 L and 200 L single-use bioreactors and a Siemens process control system at its site in Cuxhaven. The expansion represents an investment of €1.2 million ($1.35 million), Vibalogics told Bioprocess Insider, and also…

Fujifilm CDMO expands further in UK with BioCampus

Fujifilm Diosynth Biotechnologies (FDB) will construct a ‘BioCampus’ at its site in Northeast England at a cost of £12.6 million ($16.4 million) The contract development and manufacturing organization (CDMO) has announced plans to build a 42,000 square-foot expansion, set to house 250 staff members and create a further 50 jobs, at a cost of £12.6 million ($16.4 million). “The BioCampus is going to be constructed to transform the Billingham, UK site by building a state of the art office block…

Catalent’s Paragon plans second plant to support Sarepta pipeline

Fresh from an acquisition agreement by Catalent, Paragon Bioservices is seeking to establish a second manufacturing plant dedicated to produce Sarepta Therapeutics’ gene therapy pipeline. Last week, contract development and manufacturing organization (CDMO) Catalent agreed to acquire gene therapy maker Paragon for $1.2 billion (€1.1 billion). Within hours of the announcement Paragon, with Catalent’s backing, said it is seeking to establish a second manufacturing facility at its site in Anne Arundel County, Maryland for the dedicated production of Sarepta gene…

2019 BioProcess International West Event Report

At the BPI West conference in Santa Clara, CA, common themes wove throughout multiple tracks specific to process stages and levels of regulatory scrutiny. The BPI West program brings upstream and downstream experts together into the same sessions based on whether they share early or late-stage concerns. Even though special tracks addressed viral safety and technological advancements this past March, and preconference symposia focused on specific topics, a significant amount of session overlap throughout the week ensured that attendees could…

Cell therapy vendors: News from Miltenyi and Saint-Gobain

Bellicum Pharmaceuticals has inked a supply agreement with Miltenyi Biotec; Hitachi Chemical has teamed with Saint-Gobain to address manufacturing challenges – welcome to Bioprocess Insider’s cell therapy services round-up. In an SEC filing, Houston, Texas-based cellular immunotherapy firm Bellicum Pharmaceuticals revealed it has entered a agreement with Miltenyi Biotec GmbH for the supply of “certain products in connection with the development and manufacture of certain of the Company’s products.” The firm will pay Miltenyi a €2 million ($2.3 million) upfront…

Spin-out Cellular Highways looks to next-generation cell-sorting

There is no cell purification technology that allows the selection of cells based on several molecular markers at the same time while processing large batches of cells. That is until the VACS platform, new entity Cellular Highways claims. Tech firm TTP has invested £1.7 million ($2.2 million) in its spin-out firm Cellular Highway in efforts to commercialize the Vortex-Actuated Cell Sorting (VACS) platform. Bioprocess Insider (BI) spoke to Salman Samson Rogers (SSR), CEO of the new entity to find out…

Novo Nordisk making good on CAPEX pledge with $100m Danish spend

Novo Nordisk’s Kalundborg, Denmark site produces half the world’s insulin, the firm claims, as it looks to upgrade and expand its facilities. In Novo Nordisk’s end of year report, the firm announced its intentions to invest DKK 9 billion ($1.4 billion) in capital expenditure to reinforce its property, plants and equipment in 2019. This week, the Danish drugmaker made good on DKK 650 million worth of its pledge by announcing plans to upgrade and expand its insulin production site in…

AbbVie slashes 178 Stemcentrx jobs in California

AbbVie will reduce the workforce at a facility run by its acquisition Stemcentrx months after halting enrollment a Phase III trial for lead candidate Rova-T. In 2016, AbbVie acquired Stemcentrx for approximately $5.8 billion (€5.2 billion), bolstering its oncology pipeline with the addition of late-stage asset rovalpituzumab tesirine (Rova-T) in trials for small cell lung cancer (SCLC). But this month, AbbVie announced plans to cut jobs at Stemcentrx site in South San Francisco through a Californian Worker Adjustment and Retraining…